Drug-Induced Subacute Cutaneous Lupus Secondary to Sulfasalazine.

Kristal Choi, Linh Truong, Yuna Kang

Abstract readCase Reports

In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kristal ChoiDivision of Rheumatology, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA.

Linh TruongDivision of Rheumatology, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA.

Yuna KangDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a rare case of a patient with rheumatoid arthritis and Sjögren's disease who developed drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) while on sulfasalazine. Diagnosis was made by skin biopsy and confirmed by improvement of the rash with cessation of the offending medication. Sulfasalazine is implicated in drug-induced lupus erythematosus (DILE) but less so in DI-SCLE, although this may be in part due to underreporting from lack of biopsy confirmation and diagnostic uncertainty caused by the overlap in systemic and cutaneous lupus presentations. Drug-induced photosensitivity while on sulfasalazine and Sjögren syndrome-related antigen A (SSA) antibody positivity may have predisposed the patient to develop DI-SCLE in this case. It is always important to maintain a level of concern for drug-related adverse effects in a patient presenting with subacute cutaneous lupus erythematosus (SCLE) so that the offending drug can be promptly discontinued.

Indexed as

drug-induced lupusdrug-related side effects and adverse reactionsphotosensitivity disordersubacute cutaneous lupus erythematosussulfasalazine

Identifiers

PMID42005202

DOI10.7759/cureus.105393

PMCPMC13086456

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.